<table>
<thead>
<tr>
<th>Document Type</th>
<th>Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>Index Number</td>
<td>Registry 96</td>
</tr>
<tr>
<td>Version Number</td>
<td>N/A</td>
</tr>
<tr>
<td>Title</td>
<td>DRAFT_CT_Day0</td>
</tr>
<tr>
<td>Author</td>
<td>Annelot van Amerongen</td>
</tr>
<tr>
<td>Authorised By</td>
<td>N/A</td>
</tr>
<tr>
<td>Authorised On</td>
<td>N/A</td>
</tr>
<tr>
<td>Release Date:</td>
<td>N/A</td>
</tr>
</tbody>
</table>
CELLULAR THERAPY
Day 0

PRE-INFUSION

Cell collection procedure - Apheresis:

Date of collection: __ __ / __ / ___ (YYYY/MM/DD)
(If more than one collection enter the date of the first collection.)

☐ Date unknown (e.g. allogeneic product from unknown donor)

Number of collections: ____________

INDICATION FOR PLANNED CELLULAR THERAPY

Select all indications that apply:

☐ Treatment of a primary disease:

Indication diagnosis for this cellular therapy: ____________
(make sure the indication diagnosis has been registered first, using the relevant diagnosis form)

Reason for cellular therapy:

☐ Treatment of primary diagnosis
☐ Prevention of disease relapse or progression
☐ Rescue from disease relapse or progression
☐ Minimal residual disease reduction
☐ Refractory disease
☐ Other; specify: ________________

☐ Treatment or prevention of complications:
(derived from a previous treatment or expected from a subsequent treatment)

Date of the last treatment: __ __ / __ / ___ (YYYY/MM/DD)

Before continuing please make sure that the above mentioned treatment has been registered and that relevant follow-up form has been submitted; this is so relapse data and other events between transplants and/or cellular therapies can be captured.

Reason for cellular therapy:

☐ GvHD
☐ Treatment of GvHD
☐ Prevention/Prophylaxis of GvHD

☐ Graft function
☐ Graft failure treatment
☐ Prevention of rejection/Promotion of cell engraftment
☐ Graft enhancement

☐ Immune reconstitution

☐ Other indication; specify: ________________
Clinical setting:
(check only one)

- As per marketing approval / Standard of care / Institutional guidelines
- Hospital exemption
- Compassionate use / Accelerated access

Investigational drug product (IDP)/ Clinical trial

Phase: 
- 1
- 1/2
- 2
- 2/3
- 3

Blind trial: 
- No
- Yes

Randomised trial: 
- No
- Yes

EudraCT number: 

USA NCT number: 

UMIN CT number: 

Tick here if this registration should be hidden.

Date by which the registration can be made available for research: _ _ _ _ / _ _ _ _ (YYYY/MM/DD)

Cell origin:

- Autologous  (Proceed to ‘Planned cellular therapy infusion product(s)’ section on page 3)
- Allogeneic:
  - This product is manufactured from:
    - A known donor never used to treat this patient (e.g. from a donor registry or related)  (Proceed to ‘Donor information’ section on page 3.)
    - A donor that is already registered as part of a previous treatment  (Proceed to ‘Planned cellular therapy infusion product(s)’ section on page 3.)
    - An unknown donor with no data available (e.g. from a commercial product)  (Proceed to ‘Planned cellular therapy infusion product(s)’ section on page 3.)
DONOR INFORMATION

Did the donor consent to having their data in the EBMT registry?
□ No (complete only fields marked with * in this section)
□ Yes

Date of birth: __ __ / __ / __ (YYYY/MM/DD) OR:
*Age at time of donation: _____ years
If the donor was younger than 1 year:
*Age in months: _____

*Sex (at birth):
□ Male
□ Female

Donor Identification:
Donor ID given by the treating centre (mandatory): ______________________
Global registration identifier for donors (GRID): ______________________
ION code of the Donor Registry or Cord Blood Bank (mandatory): ______________________
EuroCord code for the Cord Blood Bank (if applicable): ______________________
Name of Donor Registry or Cord Blood Bank: ______________________
Donor ID given by the Donor Registry or Cord Blood Bank: ______________________
Patient ID given by the Donor Registry or Cord Blood Bank: ______________________

PLANNED CELLULAR INFUSION PRODUCT(S)

Will the planned cellular infusion product consist of more than one infusion unit?
□ No
□ Yes: Number of infusion units: _________
□ Unknown

Tissue source (check all that apply):
□ Bone marrow
□ Peripheral blood
□ Umbilical cord blood
□ Tumour
□ Other; specify: ______________________
PLANNED CELLULAR INFUSION PRODUCT(S)

Is the planned cell infusion product a commercial product?

☐ No
☐ Yes

Identification:

Name of manufacturer:

☐ Autolus
☐ Celgene/ Bristol-Myers Squibb
☐ Celyad
☐ GlaxoSmithKline (GSK)
☐ Janssen (Johnson & Johnson)
☐ Kite Gilead
☐ Miltenyi
☐ Novartis
☐ Local hospital or university
☐ Other; specify: ______________________

Name of product:

☐ Abecma
☐ Breyanzi
☐ Carvykti
☐ Kymriah
☐ Tecartus
☐ Yescarta
☐ No product name available
☐ Other; specify: ______________________
CELLULAR THERAPY

Date of (planned) cell infusion: _ _ _ / _ _ / _ _ (YYYY/MM/DD)

Center where infusion took place (CIC): ____
(if the product was not infused, report the centre where the infusion was planned to take place)

Was the cellular therapy product infused during this treatment/procedure?

☐ No: Reason why the treatment did not take place:
   Select all reasons that apply:
   - Production failure
   - Out of specification product rejected by physician
   - Disease progression or patient condition worsening
   - Patient became ineligible for treatment
   - Patient died
   - Other reason; specify: ____________________________

☐ Yes: B-cell aplasia at time of cellular therapy?
   - Absent
   - Present: Percentage of B-cells: _________ %
   - Not evaluated
**THERAPY & CELL INFUSION(S)**

**Chronological number of cellular therapy treatment for this patient:** _________
(*Please do not include any transplants the patient has had in the past*)

Complete this section only if this is the second or a subsequent cellular therapy for this patient and the previous cellular treatments cannot be registered.

If > 1:

**Same package/product as for the previous cellular therapy?**

☐ No  ☐ Yes

**Date of the last cellular therapy before this one:** _______ (YYYY/MM/DD)

**Type of the last cellular therapy before this one:**

☐ Autologous  ☐ Allogeneic: Was the same donor used both for prior and current cellular therapy?  ☐ No  ☐ Yes

**Was the last cellular therapy performed at another institution?**

☐ No  ☐ Yes: CIC (if known): _________

Name of institution: __________________________________________________________________________

City: ______________________________________________________________________________________

*If > 1 submit an annual follow-up form before proceeding using the latest assessment date before this cellular therapy; this is so relapse data and other events between transplants/cellular therapies can be captured.*

**Did the patient receive a previous HCT?**

☐ No  ☐ Yes: Date: _______ / _______ / _______ (YYYY/MM/DD)

Type: ☐ Autologous  ☐ Allogeneic

For same indication as the cellular therapy?  ☐ No  ☐ Yes
PREVIOUS THERAPIES incl. BRIDGING
(before transplant/cellular therapy)

Do not include preparative/lymphodepleting regimen. Copy and fill-in the whole 'Previous therapies incl. bridging' section for each line of treatment.

Was the patient treated before this cellular therapy procedure?
- No (proceed to 'Cellular therapy infusion unit(s)' on page 10)
- Yes
- Unknown (proceed to 'Cellular therapy infusion unit(s)' on page 10)

Has the information requested in this section been submitted with a previous HCT/cellular therapy registration for this patient? (Please note that not only treatments before HCT/cellular therapy should be reported, but also treatments that are given between HCT and cellular therapies)
- No
- Yes (proceed to 'Cellular therapy infusion unit(s)' on page 10)

Chemotherapy/Drugs given?
- No
- Yes (report in the table at page 8 and continue with questions below)
- Unknown

Radiotherapy:
- No
- Yes: Date started: __ __/__ __ (YYYY/MM/DD)
  Date ended: __ __/__ __ (YYYY/MM/DD)
- Unknown

Other treatment:
- No
- Yes; specify: ____________________________
  Date started: __ __/__ __ (YYYY/MM/DD)
  Date ended: __ __/__ __ (YYYY/MM/DD)
- Unknown
PREVIOUS THERAPIES incl. BRIDGING
(before transplant/cellular therapy) continued

Do not include preparative/lymphodepleting regimen.

<table>
<thead>
<tr>
<th>Line of treatment</th>
<th>Drug(s)/Regimen(s)*:</th>
<th>Date started: (YYYY/MM/DD)</th>
<th>Date ended: (YYYY/MM/DD)</th>
<th>Ongoing:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td><em><strong>/</strong></em>/___</td>
<td><em><strong>/</strong></em>/___</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td><em><strong>/</strong></em>/___</td>
<td><em><strong>/</strong></em>/___</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td><em><strong>/</strong></em>/___</td>
<td><em><strong>/</strong></em>/___</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td><em><strong>/</strong></em>/___</td>
<td><em><strong>/</strong></em>/___</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td><em><strong>/</strong></em>/___</td>
<td><em><strong>/</strong></em>/___</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td><em><strong>/</strong></em>/___</td>
<td><em><strong>/</strong></em>/___</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td><em><strong>/</strong></em>/___</td>
<td><em><strong>/</strong></em>/___</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td><em><strong>/</strong></em>/___</td>
<td><em><strong>/</strong></em>/___</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td><em><strong>/</strong></em>/___</td>
<td><em><strong>/</strong></em>/___</td>
<td></td>
</tr>
</tbody>
</table>

*Please consult the LIST OF CHEMOTHERAPY DRUGS/AGENTS AND REGIMENS on the EBMT website for drugs/regimens names

If there were more treatment lines, add more copies of this page.
PREVIOUS THERAPIES incl. BRIDGING
(before transplant/cellular therapy) continued

Do not include preparative/lymphodepleting regimen. Copy and fill-in the whole ‘Previous therapies incl. bridging’ section for each line of treatment.

Response to this line of treatment:
(complete only the section that is relevant to the indication diagnosis for which this cellular treatment is given)

<table>
<thead>
<tr>
<th>Acute Leukaemias:</th>
<th>Lymphomas:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>□ Complete remission (CR); maintained or achieved</td>
</tr>
<tr>
<td></td>
<td>□ Partial remission (&gt;50%)</td>
</tr>
<tr>
<td></td>
<td>□ Unconfirmed</td>
</tr>
<tr>
<td></td>
<td>□ CT scan</td>
</tr>
<tr>
<td></td>
<td>□ No response (&lt;50%)</td>
</tr>
<tr>
<td></td>
<td>□ Confirmed, by:</td>
</tr>
<tr>
<td></td>
<td>□ Progression</td>
</tr>
<tr>
<td></td>
<td>□ CT remission (CR); maintained or achieved</td>
</tr>
<tr>
<td></td>
<td>□ Not evaluable</td>
</tr>
<tr>
<td></td>
<td>□ Not evaluable</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MDS and MPN:</th>
<th>Bone marrow failure syndrome (incl. Aplastic Anaemia)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>□ Complete remission (CR); maintained or achieved</td>
</tr>
<tr>
<td></td>
<td>□ Partial remission (transfusion and growth factor independent)</td>
</tr>
<tr>
<td></td>
<td>□ No response</td>
</tr>
<tr>
<td></td>
<td>□ Progression</td>
</tr>
<tr>
<td></td>
<td>□ Not evaluable</td>
</tr>
<tr>
<td></td>
<td>□ Other</td>
</tr>
<tr>
<td></td>
<td>□ CT scan</td>
</tr>
<tr>
<td></td>
<td>□ Not evaluable</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Plasma cell disorders incl. Multiple Myeloma:</th>
<th>Solid tumours:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>□ Complete remission (CR)</td>
</tr>
<tr>
<td></td>
<td>□ Stable disease</td>
</tr>
<tr>
<td></td>
<td>□ Very good partial remission</td>
</tr>
<tr>
<td></td>
<td>□ Progression</td>
</tr>
<tr>
<td></td>
<td>□ Partial remission (PR)</td>
</tr>
<tr>
<td></td>
<td>□ Partial remission (&gt;50)</td>
</tr>
<tr>
<td></td>
<td>□ Not evaluable</td>
</tr>
<tr>
<td></td>
<td>□ VGPR or PR:</td>
</tr>
<tr>
<td></td>
<td>□ Complete remission (CR)</td>
</tr>
<tr>
<td></td>
<td>□ Stable disease</td>
</tr>
<tr>
<td></td>
<td>□ Very good partial remission</td>
</tr>
<tr>
<td></td>
<td>□ Progression</td>
</tr>
<tr>
<td></td>
<td>□ Partial remission</td>
</tr>
<tr>
<td></td>
<td>□ Partial remission (&gt;50)</td>
</tr>
<tr>
<td></td>
<td>□ Not evaluable</td>
</tr>
</tbody>
</table>

|                                            | □ Stable disease (no change; includes old MR) |
|                                            | □ Minor response (>25% and <50%) |
|                                            | □ Not evaluable |

<table>
<thead>
<tr>
<th>Haemoglobinopathy:</th>
<th>Other diagnoses:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>□ Cured</td>
</tr>
<tr>
<td></td>
<td>□ Improved</td>
</tr>
<tr>
<td></td>
<td>□ Worse</td>
</tr>
<tr>
<td></td>
<td>□ Not evaluable</td>
</tr>
<tr>
<td></td>
<td>□ No response</td>
</tr>
</tbody>
</table>

□ No transfusion required
□ Transfusions required
**CELLULAR THERAPY INFUSION UNIT(S)**

Was there more than one cell infusion unit administered during this treatment?
- [ ] No
- [ ] Yes: Number of different cell infusion units that were part of this treatment: 

---

**CELLULAR THERAPY INFUSION UNIT(S) DESCRIPTION**

*If the CT product was not infused proceed to 'Survival status' section on page 14.*

*If more than one cell infusion unit please copy and fill-in this section for each one of them.*

Unique ID of the product: ____________________
(If applicable)

Batch number: ____________________
(If applicable)

Identification of the cell infusion unit given by the centre: ____________________
(If there is only one cell infusion unit enter “1”)

Was the infused cellular product consistent with the specifications?
- [ ] No: specify the difference from specifications: ____________________
- [ ] Yes
- [ ] Unknown

Was the cellular therapy product cryopreserved prior to infusion?
- [ ] No
- [ ] Yes
- [ ] Unknown
**CELLULAR THERAPY INFUSION UNIT(S)**

**MANIPULATION**

*Complete only for non-commercial products. If more than one cell infusion unit please copy and fill-in this section for each one of them.*

**Identification of the cell infusion unit (given by the centre):** __________________________

**Manipulation:**

**Processing/Manufacturing facility:**

- [ ] Onsite, by local cell processing facility
- [ ] Offsite, by a non-commercial facility

**Gene manipulation:**

- [ ] No
- [ ] Yes: **Type**
  - [ ] Gene transfer: [ ] No
    - [ ] Yes: **Vector**: [ ] Retroviral vector
    - [ ] Lentiviral vector
    - [ ] Other vector; specify: __________________________

  - [ ] Transgene: [ ] CAR; specify all targets: __________________________
    - [ ] TCR; specify all targets: __________________________
      - [ ] specify HLA element: __________________________
  - [ ] Suicide gene; specify: __________________________
  - [ ] Other; specify: __________________________

**Gene editing:**

- [ ] No
- [ ] Yes: **Manipulated gene**: [ ] CCR5
  - [ ] Factor IX
  - [ ] Factor VIII
  - [ ] Other gene; specify: __________________________

**Other:**

- [ ] No
- [ ] Yes: specify: __________________________
### Cellular Therapy Infusion Unit(s)

**Manipulation continued**

*Complete only for non-commercial products. If more than one cell infusion unit please copy and fill-in this section for each one of them.*

**Manipulation aims:**

**Recognition of a specific target/antigen:**

- [ ] No
- [ ] Yes: **Type (check all that apply):**
  - [ ] Viral: Adenovirus
  - [ ] BK Virus
  - [ ] Covid-19 (SARS-CoV-2)
  - [ ] Cytomegalovirus (CMV)
  - [ ] Epstein-Barr virus
  - [ ] Fungal: Candida
  - [ ] Aspergillus
  - [ ] Other fungus; specify: ________________
  - [ ] Tumour/cancer antigen(s); specify all: ________________
  - [ ] Other target; specify: ________________

**Cell types administered (check all that apply):**

- [ ] CD3+ lymphocytes
- [ ] CD4+ lymphocytes
- [ ] CD8+ lymphocytes
- [ ] CD34+
- [ ] Regulatory T-cells
- [ ] Mesenchymal cells
- [ ] Dendritic cells
- [ ] Gamma-Delta cells
- [ ] NK cells
- [ ] Mononuclear cells (DLI)
- [ ] Other; specify: ________________

**Expansion:**
- [ ] No
- [ ] Yes
- [ ] Unknown

**Activation:**
- [ ] No
- [ ] Yes
- [ ] Unknown

**Induced differentiation:**
- [ ] No
- [ ] Yes
- [ ] Unknown
PREPARATIVE REGIMEN

Do not include lines of therapy given for disease treatment, bridging therapy or maintenance, these should be reported in other sections.

Preparative (conditioning) regimen given?

☐ No (Primary Immunodeficiency Disorders only)
☐ Yes

Drugs given? (any active agent, including chemotherapy, monoclonal antibody, polyclonal antibody, serotherapy, etc.)

☐ No
☐ Yes (provide details in the table on pages 14-15)
☐ Unknown
**PREPARATIVE REGIMEN continued**

**Specification and dose of the preparative regimen:**
(Report the total prescribed cumulative dose as per protocol. Multiply daily dose in mg/kg or mg/m² by the number of days; e.g. for Busulfan given 4mg/kg daily for 4days, total dose to report is 16mg/kg.)

<table>
<thead>
<tr>
<th>Chemotherapy</th>
<th>Dose</th>
<th>Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alemtuzumab</td>
<td></td>
<td>mg/m²</td>
</tr>
<tr>
<td>Anti-Thymocyte Globulin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Product name:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Origin:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Rabbit</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Horse</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Other; specify:</td>
<td></td>
</tr>
<tr>
<td>Bendamustine</td>
<td></td>
<td>mg/m²</td>
</tr>
<tr>
<td>Bleomycin</td>
<td></td>
<td>mg/m²</td>
</tr>
<tr>
<td>Busulfan</td>
<td></td>
<td>mg/m²</td>
</tr>
<tr>
<td></td>
<td>Route of administration:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Oral</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ IV</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Both</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Drug monitoring performed:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ No</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Yes; total AUC:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ mg x hr/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ micromol x min/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ mg x min/mL</td>
<td></td>
</tr>
<tr>
<td>Carboplatin</td>
<td></td>
<td>mg/m²</td>
</tr>
<tr>
<td></td>
<td>Drug monitoring performed:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ No</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Yes; total AUC:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ mg x hr/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ micromol x min/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ mg x min/mL</td>
<td></td>
</tr>
<tr>
<td>Carmustine</td>
<td></td>
<td>mg/m²</td>
</tr>
<tr>
<td>Cisplatin</td>
<td></td>
<td>mg/m²</td>
</tr>
<tr>
<td>Clofarabine</td>
<td></td>
<td>mg/m²</td>
</tr>
<tr>
<td>Corticosteroids:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Beclomethasone</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Budesonide</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Dexamethasone</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Methylprednisolone</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Prednisolone</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Cyclophosphamide</td>
<td></td>
</tr>
</tbody>
</table>

Index: Registry 96 | Title: DRAFT_CT_Day0 | Version: 0.0 | Effective Date: | THIS IS AN UNCONTROLLED COPY
**PREPARATIVE REGIMEN continued**

**Specification and dose of the preparative regimen:**
*Report the total prescribed cumulative dose as per protocol. Multiply daily dose in mg/kg or mg/m² by the number of days; e.g. for Busulfan given 4mg/kg daily for 4 days, total dose to report is 16mg/kg.*

<table>
<thead>
<tr>
<th>Chemotherapy</th>
<th>Dose</th>
<th>Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytarabine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Daunorubicin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doxorubicin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epirubicin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Etoposide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fludarabine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gemtuzumab ozogamicin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ibritumomab tiuxetan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Idarubicin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ifosfamide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imatinib</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lomustine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melphalan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mitoxantrone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paclitaxel</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rituximab</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Teniposide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thiotepa</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tositumomab</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treosulfan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other; specify*: ____________</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Please consult the **LIST OF CHEMOTHERAPY DRUGS/AGENTS AND REGIMENS** on the EBMT website for drugs/regimens names.

**Total body irradiation (TBI):**

- **No**
- **Yes:**
  - total prescribed radiation dose as per protocol: ___________ Gy
  - number of fractions: _____
  - number of radiation days: _____
CELL INFUSION EPISODE(S)

Was there more than one cell infusion episodes during this treatment or procedure?

☐ No
☐ Yes: Number of cell infusion episodes during this treatment/procedure: __________

CELL INFUSION EPISODE(S) DESCRIPTION

If more than one cell infusion unit please copy and fill-in this section for each one of them.

Date of cell infusion episode: _ _ _ / _ _ / _ _ (YYYY/MM/DD)

Route of infusion:
(check all that apply)

☐ Intravenous
☐ Intrathecal
☐ Intratumour injection
☐ Other route; specify: __________________________

Did the patient receive concomitant therapy?

☐ No
☐ Yes; specify: __________________________

Treatment given: ☐ Simultaneously to the cellular therapy
☐ After the cellular therapy episode was finished

If more than one unit was used, indicate the identification of the cell infusion given by the centre as described in the 'Cell Infusion Unit' section (This item is mandatory if more than one cell infusion unit was used): _______________________

Is the exact number of cells infused available?

☐ No
☐ Yes: Number of cells: ________________ (not adjusted for cell viability) Unit (check only one): ☐ 10⁶/kg ☐ 10⁶ ☐ 10⁷/kg ☐ 10⁸

Cell viability: __________ %

If more than one cell infusion unit was administered please copy and fill-in this section for each one of them.
## Survival Status

**Survival status:**

- [ ] Alive
- [x] Dead: **Date of death:** __/__/__(YYYY/MM/DD)

**Main cause of death:**

*(Check only one main cause)*

<table>
<thead>
<tr>
<th>Select treatment related cause:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>- [ ] Graft versus Host Disease</td>
<td></td>
</tr>
<tr>
<td>- [ ] Non-infectious complication</td>
<td></td>
</tr>
<tr>
<td>- [ ] Infectious complication: <em>(select all that apply)</em></td>
<td></td>
</tr>
<tr>
<td>- [ ] Bacterial infection</td>
<td></td>
</tr>
<tr>
<td>- [ ] Viral infection</td>
<td></td>
</tr>
<tr>
<td>- [ ] Fungal infection</td>
<td></td>
</tr>
<tr>
<td>- [ ] Parasitic infection</td>
<td></td>
</tr>
<tr>
<td>- [ ] Infection with unknown pathogen</td>
<td></td>
</tr>
</tbody>
</table>

- [ ] Relapse or progression/persistent disease
- [ ] Secondary malignancy
- [ ] Cellular therapy-related
- [ ] HCT-related
- [ ] Unknown
- [ ] Other; specify: ____________

---

**END OF CELLULAR THERAPY SECTION**

*END OF THE CELLULAR THERAPY DAY 0 REPORT*

*proceed to DISEASE STATUS AT HCT/CT/IST*
Appendix 1
-- List of transgene CAR targets --

AFP (alpha fetoprotein)
BAFF-R
BCMA
B7H3
CD11
CD16
CD19
CD20
CD22
CD30
CD33
CD38
CD56
CD123
CD138
CD171
CD229
CLL1
CS-1 (SLAMF7)
EGFR
GD2
GPRC5D
HER2
HPV-16E6
Integrinβ7
Lewis-Y
MAGE-A4
MAGE-A10
Mesothelin (MSLN)
MUC16
NKG2D
NY-ESO-1
PRAME
PSCA
SSX
Survivin
TACI
WT-1
Other (specify)